Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 1414 results for patients and public

  1. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

    In development [GID-TA10948] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  5. Cladribine for treating relapsing multiple sclerosis ID6263

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  6. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development [GID-TA11379] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  7. Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

    In development [GID-TA10611] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  8. Nemolizumab for treating prurigo nodularis [ID6451]

    In development [GID-TA11566] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  9. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  11. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

    In development [GID-TA10980] Expected publication date: 23 October 2024

    Technology appraisal guidance
    In development

  12. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  15. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development